Deadly fungus Candida auris cases detected in 27 US states — Who is at risk, symptoms, treatment

Deadly Fungus Candida auris Cases Spread Across 27 US States

Theindiapostdaily.com – The Centers for Disease Control and Prevention has confirmed that deadly fungus Candida auris cases have now been detected in 27 US states this year. This emerging pathogen poses significant public health challenges due to its growing drug resistance, lack of effective vaccines, and limited treatment options. People with weakened immune systems are particularly vulnerable to this dangerous organism, which can cause severe infections in healthcare settings.

Tracking the Outbreak: Current Statistics

According to the latest CDC data released on July 25, health officials have documented 3,437 cases of C auris nationwide. This figure represents a notable decrease from the 4,290 cases recorded during the same period last year. California continues to report the highest number of infections with 873 cases, followed by Texas with 433 and Tennessee with 283 cases.

While case numbers have been rising annually, the CDC has observed that the rate of increase has slowed since 2022. This means that although more people are being affected, the spread is not accelerating as rapidly as previously feared.

Why This Fungus Matters

Known scientifically as C auris, this yeast-like fungus causes serious medical complications in hospitalized patients. The World Health Organization has designated it as a critical-priority fungal pathogen because it can trigger various types of infections, from skin conditions to life-threatening bloodstream infections.

Normally, white blood cells produce reactive nitrogen species to destroy invading microorganisms. However, this superbug has developed the ability to suppress that natural defense mechanism, allowing it to establish infections more easily.

“It is hard to know how much C. auris contributed to their death compared to other pre-existing illnesses,” the CDC explained when discussing mortality data.

Researchers estimate that between 30 and 60 percent of infected patients die from the condition. Determining whether the fungus directly caused death or merely contributed to it alongside other health problems remains difficult. Most patients were already battling other illnesses when they contracted the infection.

How It Spreads and Who Is at Risk

Korean scientists first identified C auris in 1996, and Japanese researchers formally classified it as a separate species in 2009. The fungus spreads primarily through direct contact with infected or colonized individuals. It can also transmit indirectly through contaminated surfaces such as doorknobs, bedrails, and shared medical equipment.

One concerning characteristic is its ability to survive on surfaces and objects for extended periods. This persistence enables continued transmission between patients. Physical contact with symptomatic individuals or asymptomatic carriers who carry the organism on their skin facilitates the spread.

Healthy people generally do not need to worry about catching this infection. Medical experts emphasize that immunocompromised patients and those with weakened immune systems face substantially higher risk levels.

Treatment Options and Drug Resistance

A thorough CDC study analyzing 8,033 C auris samples collected between 2022 and 2023 uncovered important patterns regarding medication effectiveness. More than 95 percent of patients showed resistance to fluconazole, which serves as the primary first-line antifungal treatment. Additionally, 15 percent demonstrated resistance to amphotericin B, while only 1 percent resisted echinocandins. Remarkably, fewer than 1 percent of cases exhibited resistance to all three antifungal drug categories simultaneously.

Multiple strains of C auris resist at least one antifungal medication, and many resist several. The CDC recommends echinocandins as an effective treatment option for many cases, though doctors must consider individual patient factors when prescribing medication.

Frequently Asked Questions

How quickly can Candida auris spread in hospitals?

The fungus can spread rapidly through direct contact and contaminated surfaces. Healthcare facilities must implement strict infection control measures to prevent outbreaks.

What symptoms should patients watch for?

Common symptoms include skin infections, fever, and in severe cases, bloodstream infections. Patients with weakened immune systems should monitor for any unusual signs.

Are there effective treatments available?

Yes, echinocandins remain effective for most cases. However, doctors must test for drug resistance before selecting the appropriate antifungal medication.